Bensal HP ® TOPICAL OINTMENT

Manufacturer
SMG Pharmaceuticals, LLC | Dynamic Pharmaceuticals
Effective date
2024-11-20
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
9
Source
legacy-cache
Hydrated at
2026-08-01 20:48:55

Label at a glance#

ProductBensal HP
Active ingredientSALICYLIC ACID
Label structure15 sections

Indications and uses

An external treatment for the inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Indicated also in the treatment of insect bites, burns and fungal infections.

Dosage and administration

Patients should be advised to follow these step-by-step instructions for application of Bensal HP ® Ointment: Hands should be washed thoroughly. When using tubes, the tip of the tube should not come into contact with the area to be treated; the tube should be recapped tightly after each application. If applying with a cotton-tipped applicator, which is recommended, use once and discard. Bensal HP ® Ointment should...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

Prescribing Information

DESCRIPTION

DESCRIPTION SECTION

Bensal HP ® ointment contains 30 mg salicylic acid per gram in a base containing: Benzoic acid, polyethylene glycol 400, polyethylene glycol 3350 and oak bark extract (QRB-7).

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The mechanism of action of Bensal HP® is not known. While the following animal data are available, their clinical significance is unknown. It has been demonstrated that Bensal HP® significantly reduces methicillin-resistant Staphylococcus aureus (MRSA) protected by biofilms in wounds using porcine models. In addition, Bensal HP® stimulates re-epithelialization of second-degree burns in porcine models.

CLINICAL STUDIES

CLINICAL STUDIES SECTION

A randomized, double-blind, placebo-controlled study evaluated the rate of wound re-epithelialization. Four partial-thickness wounds (2×2 cm & 0.2 mm deep) were created under local anesthesia on the thighs of 13 normal, healthy, male volunteers with an electrokeratome. Bensal HP® substantially increased the rate of re-epithelialization by 63% over the vehicle alone (p<0.01) and 77% over untreated control (p<0.005).

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

An external treatment for the inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Indicated also in the treatment of insect bites, burns and fungal infections.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Bensal HP® is contraindicated for use in those patients who are hypersensitive to topical polyethylene glycols.

PRECAUTIONS

PRECAUTIONS SECTION

For external use only. Not to be used in eyes.

DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

It is not known if Bensal HP® interacts with other topical medications applied to the treatment area. The use of Bensal HP® with other topical drugs has not been studied.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Bensal HP® is generally well tolerated and non-irritating. A small percentage of patients may experience a temporary burning sensation upon application of the ointment.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Patients should be advised to follow these step-by-step instructions for application of Bensal HP® Ointment:

Hands should be washed thoroughly.

When using tubes, the tip of the tube should not come into contact with the area to be treated; the tube should be recapped tightly after each application.

If applying with a cotton-tipped applicator, which is recommended, use once and discard.

Bensal HP® Ointment should be applied twice a day for best results.

Gently rinse the area to be treated with saline or water and then pat dry. Bensal HP® Ointment can be applied directly to the wound or placed on dry gauze and then placed on the wound. Wet-Packs or Wet-To-Dry Dressings are not recommended since they will dilute the ointment and decrease its effectiveness. Bensal HP® is designed to provide moisture to the wound.

Spread a generous quantity of Bensal HP® Ointment evenly over the desired area to yield a thin continuous layer of approximately 1/8 of an inch of thickness. There may be a mild warming sensation, or slight burning, to the treated area for 3-5 minutes after application. If irritation occurs or symptoms persist after 10 days, discontinue use and consult your physician.

Try to keep the area being treated clean and exposed to air when possible. Apply an appropriate dressing to shield the area from clothes or exposure to water or dirt.

If there is no improvement in the wound within 7 days, consult your physician for further evaluation of the wound. If there is no response to the ointment at all, then the wound should be re-evaluated for other contributing factors to the wound healing process.

PEDIATRIC USE

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients has not been established.

HOW SUPPLIED

HOW SUPPLIED SECTION

30 g tubeNDC 63801 - 0107 - 01

STORAGE AND HANDLING SECTION

Store at 20° C to 25° C (68° F to 77° F), excursions permitted between 15° C and 30° C (between 59° F and 86° F). Brief exposure to temperatures up to 40° C (104° F) may be tolerated provided the mean kinetic temperature does not exceed 25° C (77° F); however, such exposure should be minimized.

SPL UNCLASSIFIED SECTION

Bensal HP® inhibited all tested microbial strains, both Gram negative and Gram positive, in a Minimum Inhibitory Concentration (MIC) test against the following 49 select pathogens.
Minimum Inhibitory Concentration Testing of QRB-7 The minimum inhibitory concentrations (MIC) of QRB-7 are listed below in parts per million (PPM)* .
MicroorganismQRB-7
MicroorganismParts Per Million
Staphylococcus aureus, ATCC 653825,000
Salmonella choleraesuis, ATCC 1070825,000
* Enterococcus faecalis, ATCC 1943350,000
Pseudomonas cepacia, ATCC 108563,125
Staphylococcus epidermidis, ATCC 1791712,500
Alcaligenes faecalis, ATCC 875025,000
Streptococcus uberis ATCC 2795812,500
Escherichia coli, ATC 2592225,000
Klebsiella pneumoniae, ATCC 1388325,000
Pseudomonas aeruginosa, ATCC 1014525,000
Shigella flexneri type 1A ATTC 919912,500
Pseudomonas paucimobilis, ATCC 298371,563
Streptococcus sanguis, ATCC 1055612,500
Acinetobacter lewoffii, ATCC 995725,000
Pseudomonas putida, HTB Isolate6,250
Aeromonas sobria, ATCC 907125,000
Staphylococcus hominus, ATCC 2784412,500
Staphylococcus haemolyticus, ATCC 2997025,000
Staphylococcus saprophyticus, ATCC 1530525,000
Staphylococcus simulans, ATCC 2784825,000
Micrococcus lylae, ATCC 2756650,000
Streptococcus agalactiae ATCC 1381312,500
Streptococcus equisimilis ATCC 954212,500
Pseudomonas alcaligenes, ATCC 1490925,000
Klebsiella oxytoca, ATCC 1576412,500
Pseudomonas stutzeri, ATCC 1758850,000
Salmonella typhi, ATCC 653912,500
Enterobacter aerogenes, ATCC 1503825,000
Group D enterococcus50,000
Trichophyton mentagrophytes CDC y68+50,000
Rhodotorula rubra HTB Isolate50,000
Enterobacter cloacae, Hosp/Envi isolate25,000
Escherichia coli, Hosp/Envi isolate25,000
Pseudomonas cepacia, Hosp/Envi isolate25,000
Klebsiella pneumoniae, Hosp/Envi isolate25,000
Staphylococcus aureus, Hosp/Envi isolate50,000
Acinetobacter calcoaceticus, ATCC 1796125,000
Alcaligenes faecalis, ATCC 33725,000
Enterobacter cloacae, ATCC 2335525,000
Achromobacter xylosoxidans, HTB isolate25,000
Salmonella typhi, ATCC 1943025,000
Listeria monocytogenes, ATCC 1531312,500
Serratia marcesans, ATCC 1475625,000
Serratia marcesans, ATCC 1388025,000
Candida albicans, ATCC 1023112,500
Serratia marcensans, Hosp/Envi isolate25,000
Salmonella enteritidis, ATCC 1307625,000
Escherichia coli, ATCC 1122925,000
Proteus mirabilis, ATCC 924025,000

* Data on file: 7 Oaks Pharmaceutical Corp., Easley, SC

SPL UNCLASSIFIED SECTION

Manufactured for: EPI Health, LLC • Charleston, SC 29403

For: 7 Oaks Pharmaceutical Corp. • Easley, SC • 877.723.6725

© 2010 7 Oaks Pharmaceuticals Corp.
BHP-PI TD 0517

PRINCIPAL DISPLAY PANEL - 30 gram Tube Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Topical Ointment
NDC 63801-0107-01

Bensal HP ®

Rx only
Net wt. 30 grams

PRINCIPAL DISPLAY PANEL - 30 gram Tube Carton
PRINCIPAL DISPLAY PANEL - 30 gram Tube Carton

FDA-Initiated Inactive NDC Indexing#

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
63801-107BENSAL HP (SALICYLIC ACID) OINTMENT [SMG PHARMACEUTICALS, LLC ]9Legacy NDC20241122_4b8ccee9-0f26-416d-a6e5-1261408df899.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
63801-107-01GM - Gram63801-107f3673167-7742-461a-884e-0857ed3d223712013-02-13
63801-107-09GM - Gram63801-1072999bd0d-af55-49cf-ad0e-2e88f53de57912013-02-13
63801-107-12GM - Gram63801-107f351ffdc-6b1e-46d3-b992-686663fd58ed12013-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Salicylic AcidACTIVE INGREDIENTO414PZ4LPZ2
Salicylic AcidACTIVE MOIETYO414PZ4LPZ2
Benzoic AcidINACTIVE INGREDIENT8SKN0B0MIM2
Polyethylene glycol 3350INACTIVE INGREDIENTG2M7P15E5P2
Polyethylene glycol 400INACTIVE INGREDIENTB697894SGQ2
Quercus rubra barkINACTIVE INGREDIENTX26K8566JX2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
63801-10763801-107-01, 63801-107-15

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 2 · 87 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PTABLET, ORALLY DISINTEGRATING / ORAL0.16 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PCAPSULE / ORAL576 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PINJECTION / INTRASYNOVIAL3 %w/vExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQLOTION / TOPICAL5 %w/wExact identifier — unii candidate
36 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMGEL / TOPICAL1 mgExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PINJECTION, SUSPENSION / INTRASYNOVIAL87 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PINJECTION / INTRAMUSCULAR56 mgExact identifier — unii candidate
28 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMSOLUTION / IRRIGATION0.02 %w/vExact identifier — unii candidate
23 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMSUSPENSION / RECTAL0.1 %w/wExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PSPRAY, METERED / NASAL96 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQSOLUTION / TOPICAL11100 mgExact identifier — unii candidate
36 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMCREAM / TOPICAL6 mgExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQSPONGE / TOPICALNAExact identifier — unii candidate
36 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMINJECTION / INTRAMUSCULAR5 %w/vExact identifier — unii candidate
23 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMGEL / RECTAL11 mgExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQOINTMENT / TOPICAL1950 mgExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PTABLET, COATED / ORAL0.5 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQTABLET, EXTENDED RELEASE / ORAL60 mgExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQINJECTION / INTRAVENOUS28216 mgExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQSWAB / TOPICAL5250 mgExact identifier — unii candidate
36 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMCREAM / VAGINAL10 mgExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PSUSPENSION / SUBCUTANEOUS2.88 %w/vExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQSOLUTION, CONCENTRATE / ORAL2813 mgExact identifier — unii candidate
36 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMINJECTION, SOLUTION / INTRAMUSCULAR0.2 %w/vExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PINJECTION, SUSPENSION / INTRA-ARTICULAR56 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PINJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR60 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQGEL / TOPICAL6300 mgExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PTABLET, FILM COATED / ORAL20 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQSPRAY, METERED / NASAL320 mgExact identifier — unii candidate
36 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMCONCENTRATE / ORAL12.5 mg/5mlExact identifier — unii candidate
23 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMLOTION / TOPICAL0.2 %w/wExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PTABLET, EXTENDED RELEASE / ORAL61 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQSUSPENSION / ORAL400 mgExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PTABLET, DELAYED RELEASE / ORAL10 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PSUSPENSION, EXTENDED RELEASE / ORAL37 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQCAPSULE, LIQUID FILLED / ORAL1122 mgExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5POINTMENT / TOPICAL1179 mgExact identifier — unii candidate
28 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMSYRUP / ORAL20 mgExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQGEL / VAGINAL1250 mgExact identifier — unii candidate
36 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMELIXIR / ORAL90 mgExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQSUPPOSITORY / VAGINAL30 mgExact identifier — unii candidate
36 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMAEROSOL, FOAM / VAGINAL0.1 %w/wExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQTABLET / ORAL193 mgExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PSUSPENSION / ORAL900 mgExact identifier — unii candidate
28 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMINJECTION / INTRAVENOUS5 %w/vExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQSUPPOSITORY / RECTAL0.25 mg/mgExact identifier — unii candidate
36 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMMOUTHWASH / BUCCALNAExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQCAPSULE / ORAL13440 mgExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQINJECTION, SOLUTION / INTRAVENOUS24186 mgExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PSUPPOSITORY / RECTAL5704 mgExact identifier — unii candidate
28 equally ranked IID candidates
Benzoic AcidBENZOIC ACID8SKN0B0MIMSOLUTION / TOPICAL0.1 %w/wExact identifier — unii candidate
23 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQSOLUTION / ORAL70200 mgExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PINJECTION, SUSPENSION / INTRAMUSCULAR87 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQCREAM / TOPICAL10 %w/wExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PINJECTION / INTRAVENOUS0.5 mlExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PSUPPOSITORY / VAGINALNAExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PTABLET, CHEWABLE / ORAL15 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQFILM, SOLUBLE / ORAL29 mgExact identifier — unii candidate
36 equally ranked IID candidates
Polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PINJECTION, SUSPENSION / SOFT TISSUE87 mgExact identifier — unii candidate
28 equally ranked IID candidates
Polyethylene glycol 400POLYETHYLENE GLYCOL 400B697894SGQAEROSOL, POWDER / TOPICALNAExact identifier — unii candidate
36 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
bb0edf4c-4215-4222-bb2a-d5e56984cbde4b8ccee9-0f26-416d-a6e5-1261408df8992024-11-20Adverse reactionsExact identifier
spl id: bb0edf4c-4215-4222-bb2a-d5e56984cbde
spl set id: 4b8ccee9-0f26-416d-a6e5-1261408df899

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.